PPLPHARMA - Technical Analysis with Chart Patterns & Indicators

Last Updated Time : 19 Sept 25, 2:16 pm

Technical Rating: 3.8

Here’s a detailed technical analysis of PPLPHARMA (Piramal Pharma Ltd)

📊 Trend Overview

Current Trend: The stock is in a mild uptrend, trading above both its 50-DMA (₹199) and 200-DMA (₹205), indicating short-term bullish momentum.

52-Week Positioning: At just 18.0% of its 52-week range (₹180 – ₹308), the stock is near its lows, suggesting potential for a rebound if momentum sustains.

📈 Momentum Indicators

RSI (59.0): Bullish zone. Indicates growing buying interest, approaching overbought territory but still safe.

MACD (2.31): Positive crossover confirms bullish momentum. The histogram is rising, suggesting continued strength.

Volume: Current volume (18.9L) is below the 1-week average (31.0L), indicating reduced participation. A volume spike would be needed to confirm breakout strength.

📉 Chart Patterns & Moving Averages

Price Action: The stock has reclaimed both DMAs and is forming higher lows, a bullish setup. A breakout above ₹210–₹215 could trigger further upside.

Support Levels

₹199 – 50-DMA and recent swing low

₹190 – psychological support

Resistance Levels

₹210–₹215 – short-term resistance zone

₹240–₹250 – previous breakdown zone

₹280–₹308 – 52-week high zone

📌 Bollinger Bands

Price is near the upper band, suggesting momentum is strong but a short-term pullback toward the middle band (~₹202) is possible before continuation.

🎯 Entry & Exit Zones

Action Price Zone (₹) Rationale

Entry 195–202 Near DMA support, favorable risk-reward

Exit (Short) 210–215 Resistance zone, potential profit booking

Exit (Long) 240–250 If breakout sustains above ₹215

🔍 Market Behavior

Trending: Yes, short-term bullish trend confirmed by MACD and price above DMAs.

Consolidating: No, price is expanding with momentum.

Reversing: Not currently. Indicators suggest continuation unless volume fades and RSI peaks.

🧠 Summary

PPLPHARMA is showing signs of recovery with price action above key moving averages and bullish momentum indicators. RSI and MACD support upside potential, though volume needs to improve for sustained breakout. Traders may consider accumulating near ₹195–₹202 and watch for breakout above ₹215 for targets toward ₹240–₹250.

Let me know if you'd like a comparative scan across mid-cap pharma or recent breakout candidates.

Edit in a page